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In a previous study, we used subcutaneous LY80 tumours (a subline of Yoshida sarcoma), Sato lung carcinoma, and
methylcholanthrene-induced primary tumours, to demonstrate that a novel water-soluble combretastatin A-4 derivative,
AC7700, abruptly and irreversibly stopped tumour blood ﬂow. As a result of this interrupted supply of nutrients, extensive
necrosis was induced within the tumour. In the present study, we investigated whether AC7700 acts in the same way against
solid tumours growing in the liver, stomach, kidney, muscle, and lymph nodes. Tumour blood ﬂow and the change in tumour
blood ﬂow induced by AC7700 were measured by the hydrogen clearance method. In a model of cancer chemotherapy
against metastases, LY80 cells (2610
6) were injected into the lateral tail vein, and AC7700 at 10 mg kg
71 was injected i.v.
ﬁve times at intervals of 2 days, starting on day 7 after tumour cell injection. The number and size of tumours were compared
with those in the control group. The change in tumour blood ﬂow and the therapeutic effect of AC7700 on microtumours
were observed directly by using Sato lung carcinoma implanted in a rat transparent chamber. AC7700 caused a marked
decrease in the tumour blood ﬂow of all LY80 tumours developing in various tissues and organs and growth of all tumours
including lymph node metastases and microtumours was inhibited. In every tumour, tumour blood ﬂow began to decrease
immediately after AC7700 administration and reached a minimum at approximately 30 min after injection. In many tumour
capillaries, blood ﬂow completely stopped within 3 min after AC7700 administration. These results demonstrate that AC7700
is effective for tumours growing in various tissues and organs and for metastases. We conclude that tumour blood ﬂow
stanching induced by AC7700 may become an effective therapeutic strategy for all cancers, including refractory cancers
because the therapeutic effect is independent of tumour site and speciﬁc type of cancer.
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The ultimate goal of cancer chemotherapy is the attack and elim-
ination of all cancer cells that develop in the body. The target of
anticancer drugs has thus inevitably become the cancer cell.
However, a chemical substance that shows strong cytotoxicity
against cancer cells has similar effects against normal cells that
are actively dividing, such as haemopoietic cells and alimentary
canal mucosa cells, resulting in severe side effects. At present, very
few drugs exhibit tumour-selective toxicity.
Many researchers have considered the possibility that tumour
growth might be suppressed by cutting off the supply of nutrients
to tumours. Two approaches are currently being studied to accom-
plish this. One is an antiangiogenic approach, which was ﬁrst
proposed by Folkman (1971). Folkman postulated that tumour
growth depends on angiogenesis and that if tumour angiogenesis
could be inhibited, an effective therapeutic strategy could be devel-
oped for solid tumours. This approach stresses inhibition of
tumour vascularisation, which is the lifeline for supply of nutrients
to tumours. To date, a number of antiangiogenic compounds have
been screened, and several are currently in clinical trials as candi-
date antiangiogenic drugs (Kerbel, 2000; Liekens et al, 2001).
The second approach was ﬁrst suggested by Algire et al (1954).
A strategic point in this approach is to shut off the tumour blood
ﬂow (TBF) into tumour tissue and thus stop the tumour’s nutri-
tional supply. Algire et al (1954) found out that podophyllotoxin
completely shut off the TBF. Podophyllotoxin was not applied
clinically, however, because of its strong toxicity. A research group
in the United Kingdom and New Zealand continued to develop
this approach and found that drugs related to ﬂavone acetic acid
and tubulin-binding agents such as vinca alkaloids markedly
decreased TBF (Bibby et al, 1989; Hill et al, 1989, 1993; Zwi et
al, 1989; Baguley et al, 1991; Ching et al, 1994; Chaplin et al,
1996; Holwell et al, 2001). However, the decrease in TBF by ﬂavone
acetic acid was accompanied by a marked reduction in systemic
blood pressure, and an effective decrease in TBF by vinca alkaloids
was achieved only at doses approaching the maximum tolerated
dose.
In 1989, Pettit et al (1989) isolated a novel compound from the
African shrub Combretum caffrum and named it combretastatin A-
4 (CS A-4). This compound was found to have potent inhibitory
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www.bjcancer.comactivity against tubulin polymerisation. Subsequently, the water-
soluble prodrug combretastatin A-4 phosphate (CS A-4-P) was
synthesised for in vivo testing. Dark et al (1997) ﬁrst demonstrated
that systemic administration of the prodrug induced a marked
decrease in vascular perfusion in experimental and human breast
cancer models in vivo. Several recent studies reported that CS A-
4-P showed antitumour effects against various kinds of tumours
without severe side effects (Horsman et al, 1998; Chaplin et al,
1999; Grosios et al, 1999; Tozer et al, 1999; Landuyt et al, 2000).
Another novel combretastatin derivative, AC7700, was synthe-
sised in Japan (Hatanaka et al, 1998; Ohsumi et al, 1998a,b). For
colon 26 adenocarcinoma, AC7700 showed stronger antitumour
effects, compared with CS A-4-P, at a dose that was an order of
magnitude lower than that of CS A-4-P (Nihei et al, 1999a). Our
research group also demonstrated that AC7700 has a remarkable
therapeutic effect against not only transplanted tumours (Hori et
al, 1999; Nihei et al, 1999b) but also methylcholanthrene-induced
autochthonous primary tumours (Hori et al, 2001), and we deter-
mined that the effect is caused by irreversible stoppage of TBF
(Hori et al, 1999).
Most investigations of the correlation between TBF and antitu-
mour effects have been performed with subcutaneous tumours.
Before clinical trials are undertaken, however, comprehensive
research is needed to determine whether AC7700 can stop the
TBF not only of subcutaneous tumours but also of tumours devel-
oping in various tissues and organs, and whether it is capable of
inhibiting the growth of systemically disseminated metastatic
tumours. This research is required because cancer chemotherapy
is usually used for patients with tumours in various internal organs
and especially patients with metastatic lesions. For such research,
therefore, we have produced solid tumours growing in the liver,
stomach, kidney, muscle tissue, and lymph nodes by implanting
tumour cells into those tissues.
The purpose of the present study was to investigate whether
AC7700 stops the TBF of tumours growing in various tissues
and organs, including lymph nodes, and whether AC7700 inhibits
the growth of tumours disseminated systemically. On the basis of
our results, we discuss the possibility that long-lasting stoppage
of TBF may become a novel therapeutic strategy against refractory
types of cancer as well as various kinds of solid tumours.
MATERIALS AND METHODS
Rats and tumour
Male Donryu rats (Crj-Donryu; Nippon Charles-River, Yokohama,
Japan), 8–10 weeks old and with an average weight of 250–300 g,
were used for TBF measurements and vital microscopic observa-
tions. Rats of the same strain, weighing 200–220 g each, were
used for the therapeutic experiment. Rats were bred and main-
tained in a ventilated, temperature-controlled (24+18C), speciﬁc
pathogen-free environment, on a bed of wood shavings, with food
and water freely available and a 12 h light–dark cycle. They were
usually housed two or three per cage. The rats were ﬁtted with
transparent chambers for microscopic observations (see below)
and were caged singly.
Tumour cells that were used included LY80, a variant of the
Yoshida sarcoma, and Sato lung carcinoma (SLC), an undifferen-
tiated lung carcinoma. In our laboratory, LY80 and SLC are
maintained by successive i.p. and s.c. transplantations, respectively.
We chose SLC for vital microscopic observations because when the
tumour is implanted in transparent chambers, demarcation
between the edge of the growing tumour and normal tissue is clear,
and therefore the change in microtumour size after therapy can
easily be measured (Hori et al, 1995). Experiments were performed
with the animals anaesthetised in a controlled-temperature box
ﬁtted with a suction duct. All experimental protocols were reviewed
by the Committee on the Ethics of Animal Experiments in our
institute and were carried out in accordance with Guidelines for
Animal Experiments issued by Tohoku University School of Medi-
cine and The Law (No. 105) and Notiﬁcation (No. 6) issued by the
Japanese Government. The ethical guidelines that were followed
meet the standards required by the UKCCCR (1998) guidelines.
Tumour cell implantation into various tissues
LY80 cells growing in ascites of a donor rat were collected,
suspended in phosphate-buffered saline, and adjusted to a concen-
tration of 2610
6 cells per 10 ml. Recipient rats were anaesthetized
with diethyl ether (Wako Pure Chemical Industries, Ltd., Osaka,
Japan). For implantation of tumour cells in the liver or stomach,
a midline incision 1.5–2 cm long was made. The tumour cell
suspension was drawn into a 50-ml graduated syringe (Hamilton
Co., Reno, NV, USA), and a 27-gauge syringe needle (27G; Termo
Co., Tokyo, Japan) was used to inject 10 ml directly into the left
lobe of the liver or into the muscularis propria in the stomach.
Injection depths were 2 and 1 mm, respectively, from the surface
of the liver and stomach. The needle holes were sealed with
synthetic resin glue (Aron Alpha 201; Toagosei Chemical Industry
Co., Tokyo, Japan). The incision wound was closed, and the
animals were allowed to recover. For tumour cell implantation into
the kidney, rats were anaesthesized and placed in the left lateral
decubitus position, and a vertical incision was made in the right
ﬂank through the skin and peritoneum to expose the lateral aspect
of the kidney. The tumour cells (2610
6 cells in 10 ml) were
implanted into the renal parenchyma by use of the above-
mentioned syringe and needle. The site of injection was 2 mm
below the renal capsule. After injection, the operation wound
was closed in one layer with thread. For tumours growing in
muscle, tumour cells (2610
6 cells in 0.1 ml) were injected into
the left biceps femoris as described for the kidney.
Lymph node metastasis
Lymph node metastasis was induced according to the method
reported previously (Hori et al, 1979). That is, the tumour cell
suspension (2610
6 cells in 10 ml) was slowly injected into the
middle of the ear by using a 27-gauge syringe needle. First, a
tumour grew only at the site of the inoculation. When the largest
diameter of the tumour was approximately 7 mm, primary
tumours were removed by cutting off the ear. After a further 7–
10 days, metastatic foci were formed in the anterior or posterior
cervical lymph node.
Drugs
AC7700 ((Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl) vinyl]
phenyl]-L-serinamide hydrochloride), one of the combretastatin
derivatives, was synthesised and provided by Ajinomoto Pharma-
ceutical Research Laboratories, Kawasaki, Japan. The intensity of
TBF stanching or antitumour activity was increased by replacing
an OH group of the B ring of CS A-4 with an NH2 group. In addi-
tion, water solubility of the compound was markedly improved by
substituting serinamide for the NH2 group. Properties of this
compound have been reported elsewhere (Hatanaka et al, 1998;
Ohsumi et al, 1998a,b). The AC7700 powder was dissolved in
0.9% NaCl solution, to give a ﬁnal concentration of 10 mg ml
71,
immediately before use. The solution (10 mg kg
71) was injected
into the tail vein at a rate of 0.15 ml min
71 by using an infusion
pump (Compact Syringe Pump; Harvard Apparatus Co., Inc.,
Millis, MA, USA). Pentobarbital sodium (Nembutal; Abbott
Laboratories, North Chicago, IL, USA) and enﬂurane (Ethrane;
Abbott Laboratories) were used for anaesthesia. Pentobarbital was
administered i.m. at a dose of 25 mg kg
71 10 min before the
experiment, and supplemental doses (12.5 mg kg
71 i.m.) were
given at 90-min intervals to maintain immobilization during the
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inhaled carrier gas at 1 l min
71 by means of an anaesthetic appa-
ratus for small laboratory animals (Hori et al, 1991).
Measurements of mean arterial blood pressure (MABP)
MABP was monitored in all rats in which TBF was measured.
MABP was measured via a catheter (PE-50; Clay Adams, Persip-
pany, NJ, USA) inserted into the right femoral artery. Pressure in
the catheter was recorded with a pressure transducer (TNF-R;
Spectramed Medical Products, Singapore), the output of which
was fed into an ampliﬁer (6M82; NEC-Sanei Co., Tokyo, Japan)
adapted for MABP measurement.
Measurement of TBF
TBF was measured with the hydrogen clearance method (Hori et al,
1991, 1996) whose principle was described in detail by Aukland et al
(1964). In brief, after saturation of the tissue with hydrogen follow-
ing inhalation of 9% hydrogen gas in air (at 1 l min
71), the blood
ﬂow value (in ml min
71 100 g
71 tissue) was calculated from the
half-life of the clearance curve obtained. A tissue blood ﬂow meter
with two separate ampliﬁers (PHG-201; Unique Medical Co., Tokyo,
Japan) was used. Two hydrogen electrodes with 80-mm diameters
(UHE-201C; Unique Medical) and two rod-type Ag/AgCl reference
electrodes (TT-98012; Unique Medical), which were inserted
between the skin and musculature in the caudal region, were used
for each rat. In some rats with tumours growing in the kidney or
liver, one electrode was inserted in the tumour and the other elec-
trode was inserted in the kidney cortex or liver within 3 mm of
the tumour nodule, for simultaneous measurement of blood ﬂow
changes in both the tumour and the adjacent normal tissue.
Blood ﬂow measurements in tumours implanted in the liver,
stomach, kidney, or muscle were performed 7–10 days postinocula-
tion. To measure the TBF of tumours growing in the liver or stomach,
laparotomy was performed at the same abdominal wall as that used
for the earlier incision, and electrodes were inserted into the tumour.
Electrodes were inserted to depths of 3 and 2 mm from the surface of
the liver tumour and the stomach tumour, respectively. For measure-
ments of the TBF in the kidney tumour, a vertical incision was
carefully made in the right ﬂank through the skin and peritoneum,
similar to the incision for implantation of the tumour, and electrodes
were inserted into the solid tumour growing in the renal parenchyma.
Electrodes were inserted to depths of 2 mm from the tumour surface.
The TBF in the intramuscular tumours was measured by introducing
electrodes to a depth of 3 mm below the tumour surface. For
measurements of TBF in lymph node metastasis, a syringe needle
(23G; Termo Co.) was used to make a pinhole in the skin overlying
a tumour growing in the cervical lymph node, and a hydrogen elec-
trode was inserted through the hole into the tumour tissue. The
electrode was inserted to a depth of 3 mm from the surface of the
skin. For TBF measurements of tumours in the kidney, muscle or
lymph nodes, rats were placed prone on a heated stage at 348C. For
tumours in the liver or stomach, rats were placed in a supine position.
Throughout the experiment, the animals were kept in the same
position, and rectal temperature was monitored with a thermistor
for small animals (PTC-201; Unique Medical) and was maintained
at 33.5–35.58C. All rats were killed with ether at the end of the
experiment. A check was performed to determine whether electro-
des were located in the tumours.
Change in TBF caused by AC7700 or 0.9% NaCl solution
By means of the same method as described previously (Hori et al,
1999), the TBF in tumours growing within the liver, stomach,
kidney, muscle, and lymph nodes was measured at multiple time
points (i.e., 10, 30, and 60 min, and every subsequent hour) until
6 h after AC7700 or 0.9% NaCl solution administration.
Rat transparent chamber and vital microscopic observation
of changes in tumour and TBF caused by AC7700
Rat transparent chambers (Hori et al, 1990) were implanted in
dorsal skin ﬂaps under aseptic conditions. Each chamber consisted
of two identical titanium frames containing a circular quartz glass
window 300 mm thick. After anaesthesia, a rat with a transparent
chamber was placed in the right lateral position on a heated stage
(MATS-SFA; Tokai HIT Co., Ltd., Tokyo, Japan), at 34.58C, which
was attached to the mechanical stage of the microscope.
AC7700 (10 mg kg
71) was administered via the lateral tail vein
by using an infusion pump. The change in TBF and the tumour
degradation process were directly observed via a light microscope
(Eclipse E800; Nikon Corporation, Tokyo, Japan) with a 106
ocular (CFI UW; Nikon) and 2–206 objectives (CFI Plan Flour;
Nikon). Tumour vessels within the chamber were transluminated
by a 12-V 100-W halogen lamp. The microscopic image was
recorded using a closed-circuit video system consisting of a CCD
video camera (CS-900; Olympus Kogaku K.K., Tokyo, Japan), a
TV monitor (PVM-14M4J; Sony Corporation, Tokyo, Japan),
and a S-VHS video recorder (SVO-2100; Sony). A video timer
was superimposed on images for record keeping. Segments of the
video tape containing desired images were transferred to computer
hard disk (Power Macintosh 8600/200, Apple Japan, Inc., Tokyo,
Japan). Final images were output by a digital printer (Pictography
4000, Fuji Photo Film Co., Ltd., Tokyo, Japan).
Chemotherapy against tumours growing in various organs
As a model for systemic metastases, LY80 cells (2610
6 cells in
0.1 ml of phosphate-buffered saline) were injected into 16 rats
via the lateral tail vein at a rate of 0.15 ml min
71 using an infusion
pump (Compact Syringe Pump). Tumour-bearing rats were
divided into two groups: group I, to which the 0.9% NaCl solution
was administered (eight rats); and group II, to which AC7700 at
10 mg kg
71 was administered (eight rats). Treatments were
performed ﬁve times at intervals of 2 days, starting on day 7 after
tumour cell injection. All rats were killed with ether and examined
macroscopically 2 days after the last treatment. For microscopic
examinations, brain, lung, heart, liver, spleen, kidney, gastrointest-
inal tract, and tumours were resected and ﬁxed in 15% formalin,
processed, and embedded in parafﬁn.
(a) Therapeutic effect of AC7700 against tumours growing in
lung, liver, heart, and subcutis In a preliminary experiment, we
had conﬁrmed that on the seventh day after i.v. transplantation of
LY80, all rats developed tumours in the lung, liver, heart, subcutis,
and visceral lymph nodes. A prominent characteristic of LY80 cells
was that they lodged in the myocardium and grew there. In the
present experiment, the therapeutic effect of AC7700 was judged
according to the difference in the number and size of tumours
growing in the lung, heart, liver, and subcutis between the
AC7700-treated group and the 0.9% NaCl-treated group. The
occurrence of ﬂuid in the thoracic cavity was also checked.
Tumours were counted in the maximum section of the left lung,
myocardium of the left ventricle, and left lobe of the liver. Each
section was projected with a proﬁle projector (V-16; Nikon) and
tumour regions were traced. The tumour area was calculated by
using an area analyser (WT-4400SE; WACOM Co., Saitama,
Japan). The weights of the skin tumours were measured with an
electronic balance (JP-3000WP; Chyo Balance Co., Kyoto, Japan).
(b) Therapeutic effect of AC7700 against lymph node
metastases The therapeutic effect of AC7700 on lymph node
metastases was evaluated by use of the difference in the number
and weight of lymph node metastases between the AC7700-treated
group and the 0.9% NaCl-treated group. All tumours visible to the
naked eye in the mediastinal, gastrointestinal, lumbar, adrenal, axil-
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Figure 1 Tumour blood ﬂow changes caused by AC7700 in tumours growing in various tissues and organs. AC7700 at 10 mg kg
71 or 0.9% NaCl solu-
tion was infused via the lateral tail vein at the rate of 0.15 ml min
71 by an infusion pump at 0 min. The TBF signiﬁcantly decreased in all tumours after
AC7700 administration compared with the control group. The TBF of tumours in the liver, muscle, and lymph node was completely stopped 30–
60 min after AC7700 administration. (A) tumour growing in the liver (open circle, 0.9% NaCl solution (n=8) vs solid circle, 10 mg kg
71 AC7700
(n=10), P=0.0007); (B) tumour growing in the muscularis propria of the stomach (open circle, 0.9% NaCl solution (n=8) vs solid circle, 10 mg kg
71
AC7700 (n=14), P=0.0118); (C) tumour growing in the kidney (open circle, 0.9% NaCl solution (n=8) vs solid circle, 10 mg kg
71 AC7700 (n=10),
P=0.0004); (D) tumour growing in the muscle (open circle, 0.9% NaCl solution (n=8) vs solid circle, 10 mg kg
71 AC7700 (n=10), P=0.0243); (E) metastatic
foci in the cervical lymph node (open circle, 0.9% NaCl solution (n=8) vs solid circle, 10 mg kg
71 AC7700 (n=10), P=0.0065).
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were measured.
(c) Therapeutic effect of AC7700 against a microtumour
growing in the transparent chamber This therapeutic effect was
evaluated by assessing the difference in the growth curve between
the AC7700-treated group and the 0.9% NaCl-treated group.
Photographs of the tumour were taken before and 24 and 48 h
after drug administration. A transparent vinyl sheet was placed
over the photograph, and the tumour was traced onto the overlay.
Tumour area was measured by an area analyser (WT-4400SE) and
was expressed as a percentage compared with the area at 0 h.
Statistics
Results were expressed as means+s.d. The statistical signiﬁcance of
TBF reduction at each time point after AC7700 administration was
evaluated with repeated measures ANOVA. Comparisons of
tumour volume, weight, and number and of the body weights of
the animals were made using Mann–Whitney U-tests. P values
of 0.05 or lower were considered signiﬁcant.
RESULTS
Effect of AC7700 on TBF in tumours growing in the liver,
stomach, kidney, and muscle, and in lymph node
metastases
Tumour blood ﬂow changes in tumours growing in the liver,
stomach, kidney, and muscle and in lymph node metastases in
response to i.v. administration of 10 mg kg
71 AC7700 or 0.9%
NaCl solution are shown in Figure 1. Tumour blood ﬂow reduc-
tion was highly signiﬁcant in all tumours in the AC7700-treated
group compared with the 0.9% NaCl-treated group. In the case
of tumours in the liver, muscle and lymph nodes, TBF was comple-
tely stopped within 1 h. When blood ﬂow changes in the normal
liver and the hepatic tumour were measured simultaneously, TBF
was almost completely stanched by AC7700, whereas the blood
ﬂow decrease in the normal liver was 30–40% at the maximum
and was reversible (data not shown). The rate of decrease and
the pattern of recovery of liver blood ﬂow were almost the same
as those reported previously (Hori et al, 1999).
The TBF decrease caused by AC7700 in the renal tumour was
completely tumour speciﬁc. Typical changes in clearance curves for
the renal cortex and renal tumour after AC7700 administration are
shown in Figure 2. In this case, although the MABP decreased tran-
siently from 113 to 80 mmHg after i.v. administration of
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Figure 2 Representative tracings of MABP and the hydrogen gas clearance curve. Upward arrow, start of 9% H2 inhalation; N, clearance curve in kidney
cortex (normal tissue); T, clearance curve in tumour growing in the kidney; downward arrow, starting point of i.v. injection of 10 mg kg
71 ml
71 AC7700;
the bold line at the bottom, chart speed 3 cm min
71; the thin line at the bottom, chart speed 60 mm min
71. Tissue blood ﬂow was calculated from the
half-life of H2 washout. Before AC7700 administration, tissue blood ﬂow in the normal kidney cortex and tumour was 157.5 and 30.9 ml min
71 100 g
71,
respectively. After AC7700 was administered i.v., MABP transiently decreased from 113 to 80 mmHg and then immediately increased to 157 mmHg. Under
AC7700-induced hypertension, although tissue blood ﬂow in the kidney cortex showed almost no change (150.7 ml min
71 100 g
71), the TBF decreased
to 13.8 ml min
71 100 g
71.
Figure 3 Photomicrograph of a measured region in a renal tumour. A
typical histological feature is present: glomerulus survives within the tumour.
H&E-stained tissue section. Original magniﬁcation, 6400. Bar, 50 mm.
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71 AC7700, it then began to increase and reached
157 mmHg. Meanwhile, TBF in the renal tumour decreased from
30.9 to 13.8 ml min
71100 g
71 within 3 min. Blood ﬂow in the renal
cortex, however, was 157.5 and 150.7 ml min
71 100 g
71 before and
after AC7700 administration, respectively. Thereafter, TBF contin-
ued to decrease, and it was approximately 8 ml min
71 100 g
71
after 6 h. However, renal cortex blood ﬂow remained approximately
150 ml min
71 100 g
71 throughout the experiment.
The effect of AC7700 on TBF in lymph node metastases was
independent of tumour size, and the TBF of all tumours, including
microfoci with a diameter of 4 mm or less, was completely
stopped.
In tumours within muscle, liver, and lymph nodes, no preexist-
ing tissues remained within the regions measured. In particular, in
lymph node metastases, even in very small growing foci (less than
4 mm in diameter), preexisting tissues were not observed (data not
shown). In contrast, in renal tumours, even in tumours with a
diameter greater than 8 mm, glomeruli survived within regions
assayed (Figure 3).
Antitumour effect of AC7700 against tumours growing in
various tissues and organs
Effects of AC7700 on growth of tumours developing in the lung,
liver, heart, subcutis, and visceral lymph nodes are shown in Figure
4A–E. The size of tumours in the lung and subcutis and the
number of lymph node metastases were signiﬁcantly suppressed
in the treatment group compared with the control group. Growth
of the tumours in the liver and heart tended to be inhibited by
AC7700. Haemothorax was observed in four of eight rats in the
control group, and those rats had large tumours in the lung and
the mediastinal lymph node. In the AC7700-treated group, in
contrast, the growth of those tumours was markedly suppressed,
and, therefore, no rats had haemothorax. There was no signiﬁcant
difference in body weight between the AC7700-treated group and
the control group (P=0.1069) (Figure 4F). No obvious side effects,
such as anaemia or diarrhoea, were observed at the AC7700 dose
used in the protocol of this treatment. This experiment was
repeated twice using the same protocol, with similar results.
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
s
T
u
m
o
u
r
 
a
r
e
a
 
(
m
m
2
)
30
20
10
0
0.9% NaCI AC7700
A
T
u
m
o
u
r
 
a
r
e
a
 
(
m
m
2
)
25
20
15
10
5
0
0.9% NaCI AC7700
B
T
u
m
o
u
r
 
a
r
e
a
 
(
m
m
2
)
7
6
5
4
3
2
1
0
C
W
e
i
g
h
t
 
o
f
 
s
.
c
.
 
t
u
m
o
u
r
 
(
g
)
2
0.5
1
0.5
0
D
0.9% NaCI AC7700 0.9% NaCI AC7700
(continued overleaf)
Tumour blood flow stanching and antitumour effects
K Hori et al
1609
ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(10), 1604–1614E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
s
W
e
i
g
h
t
 
o
f
 
m
e
t
a
s
t
a
t
i
c
 
f
o
c
i
 
(
g
)
6
5
4
3
2
1
0
E
0.9% NaCI AC7700
B
o
d
y
 
w
e
i
g
h
t
 
(
g
)
250
200
150
100
50
0
F
024681 0 1 2 1 4 1 6
Days after i.v. injection of tumour cells
Figure 4 Antitumour effect of AC7700 against tumours growing in various tissues. The left side in each panel shows results for the group given 0.9% NaCl
(eight rats); the right side in each panel shows results for the group treated with 10 mg kg
71 AC7700 (eight rats). The sum of tumours that appeared in rats
in each group is shown in each panel. (A) tumours in the lung; (B) tumours in the liver; (C) tumours in the myocardium; (D) tumours in the subcutis; (E)
lymph node metastases (mediastinale, coeliacum, mesentericum, lumbare); (F) changes in body weight of tumour-bearing rats during AC7700 treatment.
(A–C), mean tumour area+s.d. (mm
2) in the maximum sections of the left lung, the left lobe of the liver, and the myocardium of the left ventricle. (D) and
(E) mean tumour weight+s.d. (g) in the subcutis and lymph node metastases. Tumour size in the lung and subcutis in the AC7700-treated group was
signiﬁcantly smaller than that in the 0.9% NaCl-treated group (lung tumour, P=0.0228; subcutaneous tumour, P50.0001). The number of lymph node me-
tastases was signiﬁcantly smaller in the AC7700-treated group compared with the control group (P=0.0054). There was no signiﬁcant difference in body
weight between the two groups.
Figure 5 Blood ﬂow stasis in tumour capillaries caused by 10 mg kg
71 AC7700. (A) before AC7700 administration; (B) 3 min later; (C) 5 min later; (D)
20 min later. Tumour blood ﬂow in this region completely stopped approximately 2 min after the AC7700 administration. Original magniﬁcation, 6100.
Bar, 100 mm.
Tumour blood flow stanching and antitumour effects
K Hori et al
1610
British Journal of Cancer (2002) 86(10), 1604–1614 ã 2002 Cancer Research UKVital microscopic observation of TBF change and
therapeutic effect caused by AC7700
Tumour blood ﬂow always began to decrease immediately after
AC7700 administration and completely stopped within 30–
60 min. An example of AC7700-induced TBF cessation in a
tumour microcapillary is shown in Figure 5. In this case, TBF
completely stopped within 3 min after i.v. injection of 10 mg kg
71
AC7700. Arterioles in normal tissue and arterioles feeding into
tumours markedly contracted after AC7700 administration (Figure
6). During this continuous arteriolar contraction, the TBF comple-
tely stopped; the MABP rose simultaneously with the contraction
of these arterioles.
Figure 7 shows the effect of a single i.v. injection of 10 mg kg
71
AC7700 or 0.9% NaCl solution on the size of a microtumour
growing in the transparent chamber. The area doubling time of
the SLC tumour was 41.7+11.4 h (n=4) in the control group.
However, tumours completely stopped growing during 48 h of
observation after administration of AC7700 (n=4). One example
of the therapeutic effect of AC7700 against a small SLC tumour
with a diameter of less than 3 mm is shown in Figure 8. Tumour
blood ﬂow in the whole area of the tumour was completely shut
off, and the colour of the tumour changed from white to brown
within 24 h after administration of AC7700 (Figure 8A–D). Histo-
logical examination 48 h later conﬁrmed that this tumour had
become necrotic (Figure 8E, F). In contrast, the colour of the
tumour in the control group did not change at all, and the tumour
continued to grow during the observation period (Figure 9).
DISCUSSION
The present study clearly demonstrated that i.v. administration of
AC7700 strongly stanched TBF not only in subcutaneous tumours
(Hori et al, 1999, 2001) but also in tumours growing in various
kinds of tissues and organs, including lymph node metastases,
and that the stanched TBF suppressed tumour growth in all regions
of the body. In all tumours, AC7700-induced TBF cessation was
completed within 30–60 min after i.v. administration of the drug
and was maintained during the experimental period of 6 h. This
result was analogous to that obtained with subcutaneous tumours
(Hori et al, 1999). In tumours growing in muscle, liver, and lymph
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Figure 6 Contraction of a host arteriole and a tumour-feeding arteriole caused by 10 mg kg
71 AC7700. (A) before AC7700 administration; (B) 5 min
later; (C) 30 min later; (D) 3 h later. Tumour blood ﬂow completely stopped 30 min after i.v. administration of AC7700. Note that an arteriole (white
arrow) underwent marked contraction in response to AC7700, and a feeding arteriole (asterisk) into a tumour disappeared from view. Original magniﬁca-
tion, 620. Bar, 250 mm.
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Figure 7 Inhibition of SLC tumour growth caused by AC7700 in the tu-
mour developing in a transparent chamber. Tumour size at the start of ob-
servation was deﬁned as 100%. During the 48 h after a single i.v.
administration of 10 mg kg
71 AC7700, tumour size did not change at all
(solid circle) (n=4). In contrast, tumours in the control group continued
to grow (open circle) (n=4). Tumour area doubling time was 41.7+11.4 h.
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the lymph node was completely shut off, even in small metastases
with diameters less than 4 mm, whose initial blood ﬂow was often
higher than 80 ml min
71 100 g
71. This is a noteworthy phenom-
enon that could be exploited as a therapeutic strategy against
micrometastases in lymph nodes.
Denekamp et al (1983) investigated the effect of TBF on tumour
growth by mechanically stopping the TBF and found that if stop-
page was continued for more than 18 h, tumours never showed
renewed blood circulation and lost the ability to grow. We reported
in a previous paper (Hori et al, 1999) that once the TBF was
stopped by AC7700, it did not recover within tumours, even
24 h after drug administration in many regions. The present study
shows that the more complete the TBF stanching, the stronger the
inhibitory effect against tumour growth. In fact, for even a small
tumour with a diameter of less than 3 mm growing in a transpar-
ent chamber, if the TBF cessation was complete and long-lasting,
the whole region, including the peripheral rim of the tumour,
became necrotic and tumour growth eventually stopped. In the
AC7700-treated group, the reduced number of lymph node metas-
tases was certainly caused by complete TBF stanching in these
metastases.
Simultaneous measurement of blood ﬂow in the renal cortex
and the renal tumour showed that the TBF decreased markedly
as a result of AC7700, but blood ﬂow in the renal cortex hardly
changed, even in regions only 3 mm from the tumour edge.
However, TBF stanching in renal tumours was not as complete
as that in tumours growing in other organs. The reason for this
difference is probably related to the fact that many glomeruli,
which naturally have high blood ﬂow, sporadically survived in
measured tumours.
We previously showed (Hori et al, 1999) that although the
blood ﬂow in normal tissues tended to decrease at the dose of
AC7700 used in this study, it was never shut off. The decrease
was comparatively small and reversible in most cases. We consid-
er this to be the reason that AC7700 can induce selective tumour
necrosis without causing severe damage to normal tissues or
organs. Although the degree of blood ﬂow decrease in normal
tissues was not as large as that in tumours, except in bone
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Figure 8 Typical ﬁnding of growth inhibition caused by AC7700 in an SLC microtumour developing in a transparent chamber. (A) before administration
of 10 mg kg
71 AC7700 administration; (B) 3.5 h after administration of AC7700; (C) 25 h later; (D) 48 h later; (E) histology 48 h later. Tumour blood
ﬂow completely stopped at 1 h after a single i.v. administration of AC7700. The whole region of the tumour, with a diameter of 2.5 mm, became necrotic.
Tumours stopped growing completely during the 48-h observation period. Histological study (E and F, H&E stained) certiﬁed the tumour (shown on the
right side) as necrotic. Original magniﬁcation: A–D, 620; E, 6200; F, 6400. Bars: A–D, 500 mm; E, 100 mm; F,5 0mm.
Figure 9 Typical ﬁnding of growth of an SLC tumour developing in a
transparent chamber in the control group. (A) 0 h; (B) 24 h later; (C)
48 h later. The tumour never stopped growing during the observation per-
iod. Original magniﬁcation, 620. Bar, 500 mm.
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should be carefully chosen, because in older patients with
compromised perfusion in organs such as heart and brain, a
slight reduction in perfusion may have serious consequences.
It has not yet been sufﬁciently clariﬁed why AC7700 causes TBF
to stop and why the TBF stoppage is irreversible, whereas the
decrease in blood ﬂow in normal tissues is reversible. Some authors
speculate that TBF stanching due to a combretastatin compound
may be caused by a direct effect of the drug on tumour vessel
endothelial cells (Dark et al, 1997; Grosios et al, 1999). However,
in vivo evidence for this suggestion has not yet been provided.
Although it is not clear whether TBF stanching is caused by direct
action of this compound on tumour vessels, it seems quite likely
that some structural change would occur in tumour vessels in
any site after AC7700 administration.
Tumour vessels, even large-calibre vessels, usually consist of
only a monolayer of endothelial cells and have no pericytes or
smooth muscle cells for a supporting structure; sometimes a
basement membrane cannot be observed at all or only incomple-
tely (Papadimitriou and Woods, 1975; Konerding et al, 1989).
Normal vessels, in contrast, are usually supported by pericytes
and a continuous basement membrane (Simionescu and Simio-
nescu, 1984). The difference in blood ﬂow change between
normal and tumour tissues may be related to this different
vessel architecture. In fact, we observed that lumens of many
tumour vessels that had rich blood ﬂow and thus a large
volume at the time of AC7700 administration completely ﬂat-
tened after the TBF was shut off; normal capillaries did not
ﬂatten out, even after blood was no longer present in vessels,
and lumen morphology was retained (in preparation for submit-
ting). We are now obtaining data suggesting that strong and
long-lasting vasoconstriction of arterioles and tumour-feeding
arterioles leads to irreversible TBF stoppage and thus extensive
tumour cell death. We will describe in detail the microvascular
mechanism of TBF stanching caused by AC7700 in a separate
paper.
In summary, AC7700 stopped TBF at a dose that did not cause
severe side effects regardless of the growing site of the tumour and
markedly suppressed tumour growth. The efﬁcacy of cancer
chemotherapy based on TBF stanching is in theory independent
of the type of cancer cell. Accordingly, this strategy may become
a powerful therapeutic tool against refractory cancers, and
AC7700 is a promising anticancer compound that shows such
effects.
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